[1] T. Attachaipanich, S. C. Chattipakorn, and N. Chattipakorn, “Potential Roles of Melatonin in Doxorubicin-Induced Cardiotoxicity: From Cellular Mechanisms to Clinical Application,” Pharmaceutics, vol. 15, no. 3, p. 785, 2023.
[2] P. S. Rawat, A. Jaiswal, A. Khurana, J. S. Bhatti, and U. Navik, “Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism and novel therapeutic strategies for effective management,” Biomed. Pharmacother., vol. 139, p. 111708, 2021.
[3] J. Herrmann, “Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia,” Nat. Rev. Cardiol., vol. 17, no. 8, pp. 474–502, 2020.
[4] B. B. Hasinoff and E. H. Herman, “Dexrazoxane: How it works in cardiac and tumor cells. Is it a prodrug or is it a drug?,” in Cardiovascular Toxicology, vol. 7, no. 2, pp. 140–144, 2007.
[5] D. S. Monahan, E. Flaherty, A. Hameed, and G. P. Duffy, “Resveratrol significantly improves cell survival in comparison to dexrazoxane and carvedilol in a h9c2 model of doxorubicin induced cardiotoxicity,” Biomed. Pharmacother., vol. 140, p. 111702, 2021.
[6] J. A. Smith et al., “Is it equivalent? Evaluation of the clinical activity of single agent Lipodox® compared to single agent Doxil® in ovarian cancer treatment,” J. Oncol. Pharm. Pract., vol. 22, no. 4, pp. 599–604, 2016.
[7] S. Sritharan and N. Sivalingam, “A comprehensive review on time-tested anticancer drug doxorubicin,” Life Sci., vol. 278, p. 119527, 2021.
[8] S. Ojha et al., “Cardioprotective potentials of plant-derived small molecules against doxorubicin associated cardiotoxicity,” Oxid. Med. Cell. Longev., vol. 2016, 2016.
[9] I. P. Singh and S. Mahajan, “Berberine and its derivatives: a patent review (2009–2012),” Expert Opin. Ther. Pat., vol. 23, no. 2, pp. 215–231, 2013.
[10] Y. Cai et al., “A new therapeutic candidate for cardiovascular diseases: Berberine,” Front. Pharmacol., vol. 12, p. 631100, 2021.
[11] C. S. Liu, Y. R. Zheng, Y. F. Zhang, and X. Y. Long, “Research progress on berberine with a special focus on its oral bioavailability,” Fitoterapia, vol. 109, pp. 274–282, 2016.
[12] J. Niu et al., “Berberine-loaded thiolated pluronic f127 polymeric micelles for improving skin permeation and retention,” Int. J. Nanomedicine, vol. 15, pp. 9987–10005, 2020.
[13] V. Kuete, O. Karaosmanoğlu, and H. Sivas, “Anticancer Activities of African Medicinal Spices and Vegetables,” in Medicinal Spices and Vegetables from Africa: Therapeutic Potential Against Metabolic, Inflammatory, Infectious and Systemic Diseases, Elsevier, 2017, pp. 271–297.
[14] C. Siebel, C. Lanvers-Kaminsky, G. Würthwein, G. Hempel, and J. Boos, “Bioanalysis of doxorubicin aglycone metabolites in human plasma samples–implications for doxorubicin drug monitoring,” Sci. Rep., vol. 10, no. 1, pp. 1–7, 2020.
[15] Y. J. Wu, L. F. Li, and J. H. Meng, “Study on the Pharmacokinetics of Berberine,” J. Math. Med., vol. 21, pp. 217–219, 2008.
[16] M. Ghezzi et al., “Polymeric micelles in drug delivery: An insight of the techniques for their characterization and assessment in biorelevant conditions,” J. Control. Release, vol. 332, pp. 312–336, 2021.
[17] Z. Wang, P. Chen, M. Guo, X. Yang, W. Song, and F. Huang, “Physicochemical Characterization of Berberine-loaded Pluronic F127 Polymeric Micelles and In Vivo Evaluation of Hypoglycemic Effect,” J. Pharm. Innov., pp. 1–10, 2022.
[18] M. H. Shahid, I. Anjum, M. N. Mushtaq, and S. Riaz, “Cardioprotective effect of boswellic acids against doxorubicin induced myocardial infarction in rats.,” Pak. J. Pharm. Sci., vol. 34, 2021.
[19] G. C Pereira, A. M Silva, C. V Diogo, F. S Carvalho, P. Monteiro, and P. J Oliveira, “Drug-induced cardiac mitochondrial toxicity and protection: from doxorubicin to carvedilol,” Curr. Pharm. Des., vol. 17, no. 20, pp. 2113–2129, 2011.
[20] Y. Z. Wu, L. Zhang, Z. X. Wu, T. T. Shan, and C. Xiong, “Berberine Ameliorates Doxorubicin-Induced Cardiotoxicity via a SIRT1/p66Shc-Mediated Pathway,” Oxid. Med. Cell. Longev., vol. 2019, 2019.
[21] F. Gholampour and S. Keikha, “Berberine protects the liver and kidney against functional disorders and histological damages induced by ferrous sulfate,” Iran. J. Basic Med. Sci., vol. 21, no. 5, p. 476, 2018.
[22] J.-S. Moon et al., “NOX4-dependent fatty acid oxidation promotes NLRP3 inflammasome activation in macrophages,” Nat. Med., vol. 22, no. 9, pp. 1002–1012, 2016.
[23] A. Riad et al., “Toll‐like receptor‐4 deficiency attenuates doxorubicin‐induced cardiomyopathy in mice,” Eur. J. Heart Fail., vol. 10, no. 3, pp. 233–243, 2008.
[24] Y.-P. Yuan et al., “CTRP3 protected against doxorubicin-induced cardiac dysfunction, inflammation and cell death via activation of Sirt1,” J. Mol. Cell. Cardiol., vol. 114, pp. 38–47, 2018.
[25] Z. Qin-Wei and L. I. Yong-Guang, “Berberine attenuates myocardial ischemia reperfusion injury by suppressing the activation of PI3K/AKT signaling,” Exp. Ther. Med., vol. 11, no. 3, pp. 978–984, 2016.
[26] M. Olsson and B. Zhivotovsky, “Caspases and cancer,” Cell Death Differ., vol. 18, no. 9, pp. 1441–1449, 2011.
[27] L. J. Carlson, B. Cote, A. W. G. Alani, and D. A. Rao, “Polymeric micellar co-delivery of resveratrol and curcumin to mitigate in vitro doxorubicin-induced cardiotoxicity,” J. Pharm. Sci., vol. 103, no. 8, pp. 2315–2322, 2014.
[28] A. Abdulredha, M. Abosaooda, F. Al-Amran, and N. R. Hadi, “Berberine protests the heart from ischemic reperfusion injury via interference with oxidative and inflammatory pathways,” Med. Arch., vol. 75, no. 3, p. 174, 2021.